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Abstract: With cervical cancer screening the choice of 1-year as a period of follow-up in positive high-risk HPV 
women without cytological lesions is still under discussion. We evaluated the management of these women and the 
role of HPV genotyping test. We did a cervical cancer screening study of women aged 35-64 with primary high-risk 
HPV test. Women positive for high-risk HPV with negative cytology were followed-up after 1 year. In this study we 
selected women with high-risk HPV+/PapTest- resulted high-risk HPV+ at recall and performed the PapTest and HPV 
genotyping test. The detection rate of squamous high grade (CIN2+) relative to the total screened cohort was 2.1‰, 
and it was 0.2‰ at the 1-year recall. The colposcopy performed in women referred at the 1-year recall accounted 
for 48.8% of the total (baseline + 1-year recall), and 84.3% of these women had no cytological lesions. The most 
frequent hr-HPV genotype detected was HPV16 and 66.7% of co-infections were due to HPV16 and HPV18. 54.5% 
of women presented a persistent infection at 1-year recall with the same HPV subtype, 50% of persistent infections 
was due to HPV16 and 16.7% of these were determined to be CIN2+ histological lesions. Our data show that it may 
be useful to extend the period of follow-up for women hr-HPV+/PapTest- so as to reduce the number of unnecessary 
colposcopies due to the transitory infections and that the genotyping test could help to identify the persistent infec-
tions in which HPV16 is involved. 
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Introduction
Cervical cancer represents the fourth most 
common cancer in women worldwide [1]. The 
strength of cervical screening is the possibility 
to get an early diagnosis of high grade cervical 
intraepithelial neoplasia (CIN2+), the precursor 
lesion of invasive cervical cancer, before the 
appearance of symptoms [2, 3]. It is well estab-
lished that Human Papillomavirus (HPV) infec-
tion is a necessary condition for cervical cancer 
development [4] and recently, the use of molec-
ular methods for the detection of HPV DNA in 
cervical cell samples was proposed [5]. The 
International Agency for Research on cancer 
has identified 12 high-risk HPV (hr-HPV), clas-
sifying them as carcinogens [6]. The use of 
automatized molecular test to detect hr-HPV in 
cervical screening increases the diagnostic 
capability of CIN2+compared to PapTest [7, 8], 
especially in women 35 years of age and over 
[9, 10]. Given this evidence, the Italian screen-
ing guidelines of GISCi (Italian Association of 
Cervical Screening Programs) actually recom-
mend the use of Hybrid Capture 2 hr-HPV DNA 
test (HC2; Qiagen, Gaithersburg, MD) as prima-
ry screening test in women aged 35-64 [3, 11]. 
Nevertheless, HPV infection is very common 
and usually clears spontaneously within 1-2 
years [12, 13] and an appropriate cytological 
triage is considered a necessary strategy to 
maintain an adequate level of specificity of the 
test and to avoid unnecessary colposcopies 
and possible over-diagnosis [3, 14]. The GISCi 
guidelines in case of normal cytology after a 
positive molecular test (hr-HPV+/PapTest-) rec-
ommend that women be recalled to perform 
HC2 test after 1-year and, if they result positive 
again, they are to be directly referred forcolpos-
copy [3].
1-year follow-up of Hr-HPV+/PapTest- women
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A critical issue of HPV screening program that 
can affect the screening efficacy, is the compli-
ance to 1-year recall of women hr-HPV+/
PapTest- at baseline [14], indeed the choice of 
1-year as a period of follow-up is still subject 
matter for discussion [15, 16]. Currently, it has 
been hypothesized that the use of HPV geno-
typing tests that identified specific HPV sub-
types could improve the screening program 
[17]. However, literature data is not yet suffi-
cient to confirm that view.
The aim of the study was to assess the follow-
up period of hr-HPV+/PapTest- women in order 
to understand if 1 year is the correct period to 
be able to identify CIN2+ lesions without 
increasing unnecessary colposcopies. More- 
over, we will try to understand if the genotyping 
test could improve the effectiveness of the 
screening program.
Materials and methods 
Study population 
The Pathology Unit of ICOT Hospital, Department 
of Medical-Surgical Sciences and Bio-
Technologies, Sapienza University of Rome and 
Screening Unit of Local Health Unit of Latina, 
have been running a new organized cervical-
screening in the Latina district since 2012. The 
study population include women aged 35-64, 
which were invited by mail to perform HC2 test 
from April 2012 to June 2013 that had resulted 
hr-HPV+/PapTest- at baseline and that were 
recalled to perform HC2 test after 1 year. hr-
HPV+ women at the 1-year recall were referred 
to colposcopy in accordance with GISCI guide-
lines. Therefore, we invited the hr-HPV+ women 
at the 1-year recall to perform PapTest (BD 
SurePathTM, Franklin Lakes, NJ, USA) and we 
performed the HPV sign® Genotyping Test 
(Diatech Pharmacogenetics, Jesi, IT) in all 
women hr-HPV+/PapTest+ at the 1-year recall, 
in selected women hr-HPV+/PapTest- at the 
1-year recall and on samples of the same 
women at baseline. We used the women hr-
HPV- at the 1-year recall as control. 
Hybrid capture 2 high-risk HPV DNA test (HC2)
Exfoliated cervical cells were collected using a 
cytobrush and eluted in the Sample Transport 
Medium (STM, Qiagen, Hilden, DE). Cervical 
specimens were denatured to disrupt the virus 
and release the target DNA. The RNA probes 
were diluted in a probe diluent and once loaded 
all the samples, calibrators, controls and 
reagents, the hybridization phase began 
according to supplier’s instructions. The chemi-
luminescent reaction was measured by lumi-
nometer (DML instrument, Qiagen, Hilden, DE) 
and the emitted light was measured as RLU. 
For each reaction were used three negative 
controls, three positive controls, one quality 
control for low-risk HPV (lr-HPV) and one quality 
control for hr-HPV. The HPV subtypes detected 
Figure 1. Flowchart and main 
data of the HPV-based screen-
ing programme.
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by the assay are 12 hr-HPV (HPV-16, 18, 31, 
33, 35, 39, 45, 51, 52, 56, 58, 59) and 1 prob-
able carcinogen HPV subtype (HPV 68), without 
determining the specific HPV subtype present 
in the sample. Samples that showed a RLU ≥ 1 
pg/ml were considered positive. After HC2 test, 
the specimens were stored at -20°C.
Cytology: Pap test
The cervical cell samples were obtained by 
using a cytobrush and were put in PreservCyt 
solution; liquid-based cytology was performed 
by using the Sure Path system (BD SurePathTM, 
Franklin Lakes, NJ, USA). One slide per woman 
was prepared according to the supplier’s 
instructions. Cytological and histological diag-
nosis was reported according to 2001 Bethesda 
System [2]. 
HPV sign® genotyping test
Total DNA was extracted from the same STM 
sample used previously for HC2 test by QIAamp 
DNA Mini Kit (Qiagen, Hilden, DE) following the 
manufacturer’s instructions. The concentration 
and quality of extracted DNA was assessed by 
amplification of housekeeping gene β-actin on 
Agilent Bioanalyzer (Agilent Technologies, 
Waldbronn, DE). For each sample, according to 
the supplier’s instructions, a hypervariable 
region of a highly conserved HPV L1 gene was 
amplified by Real-Time PCR (Rotor-Gene Q, 
Qiagen, Hilden, DE) based on EvaGreenTM dye 
chemistry, using human β-globin gene as inter-
nal control. A negative control and four positive 
controls provided by the manufacturer were 
included in the process. Samples that showed 
amplification of HPV L1 gene were considered 
suitable for pyrosequencing. 20 µL of biotinyl-
ated amplification products were immobilized 
in the sepharose beads coated with streptavi-
din (Streptavidin SepharoseTM High Perfor- 
mance, GE Healthcare Bio-Sciences AB, 
Upsala, SE). Immobilized amplification prod-
ucts were denatured and washed using 
PyroMark Q24 Vacuum Workstation (Qiagen, 
Hilden, DE) and subsequently they were anneal-
ing with four sequencing primers recognizing a 
broad spectrum of HPV subtypes, including hr-
HPV (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 
56, 58, 59), intermediate-risk (ir-HPV: HPV26, 
53, 66, 67, 68, 73, 82, 84, 90, 91) and lr-HPV 
(HPV6, 11, 34, 40, 42, 43, 44, 54, 70, 72, 81, 
89). At the end of this step, the clinical samples 
and the positive controls were mixed with 
enzymes, substrate, dNTP (Qiagen, Hilden, DE) 
and they were processed for sequencing reac-
tion. Pyrosequencing was performed on 
PyroMark Q24 instrument (Qiagen, Hilden, DE) 
and results were analyzed using IdentiFire ver-
sion 1.0.5.0 software package (Biotage AB, 
Uppsala, SE). The identification of HPV geno-
type was considered correct if the score of the 
correlation between the reference sequence 
and the sequence of the clinical sample was 
higher than or equal to 85%.
Results
32,988 women aged 35-64, were invited to 
perform HC2 test in health district of Latina 
from April 2012 to June 2013 and 9,941 (30%) 
Table 1. Results of HPV screening program in women aged 35-64  
 Baseline HPV+/PapTest- at the 1-year recall
 N % ‰ N % ‰
Women invited 32,988   400  
Women screened 9,941 30 298 74.5
Compliance to HC2 test 9,941/32,988 30  298/400 74.5  
Proportion of HPV positive tests 556/9,941 5.6  149/298 50  
Proportion of HPV+/Pap test + 156/556 28  10/64* 15.6  
Proportion of HPV+/Pap test - 400/556 72  54/64* 84.3  
Referral rate to colposcopy 156/9,941 1.5  149/9.941 1.5  
Compliance to colposcopy 150/156 96  140/149 94  
PPV for CIN2+ 21/150 14  2/140 1.4  
DR CIN2+ relative to the total 21/9,941 2.1 2/9,941  0.2
DR CIN2+ at recall    2/298  6.7
Overall DR CIN2+ 23/10239  2.25    
*234 women who didn’t want to perform PapTest.
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were screened, as detailed in Figure 1. Overall, 
556 (5.6%) women resulted hr-HPV+ at base-
line and 156 (28%) of them resulted positive to 
PapTest. Women hr-HPV+/Pap test- (400, 72%) 
were invited to repeat hr-HPV test after 12 
months, with referral rate (RR) for HC2 test to 
1-year of 4%. Among these, 298 (74.5%) attend-
ed to the hr-HPV test: 149 (50%) resulted still 
positive to hr-HPV test and were directly 
referred to colposcopy, with RR for colposcopy 
to 1-year of 1.5%. Overall, 140 (94%) women 
were examined and 82 (58.6%) presented a 
positive colposcopy result, moreover, CIN1 and 
CIN2+ were detected in 77 (94%) and 2 (2.4%) 
cases, respectively (Figure 1). The detection 
rate (DR) for CIN2+ at the 1-year recall was 
6.7‰ (2/298), while the positive predictive 
value (PPV) for CIN2+ was 1.4%. The DR for 
CIN2+ at the 1-year recall relative to the total 
screened cohort was 0.2‰ (2/9941) while the 
overall DR for CIN2+ of the HPV program (base-
line and 1-year recall) was 2.2‰ (23/10239). 
The proportion of CIN2+ detected at the 1-year 
recall was 0.67% (2/298) (Table 1).
For the aim of our study, 64 (43%) women hr-
HPV+ at the 1-year recall agreed to be subject-
ed to the Pap test and 10 (15.6%) of them pre-
sented a positive cytology result. Atypical 
squamous cells of undetermined significance 
(ASC-US) was detected in 1 (10%) case, low-
grade squamous intraepithelial lesion (L-SIL) 
was detected in 6 (60%) cases, atypical squa-
mous cells-cannot exclude high grade SIL (ASC-
H) in 2 (20%) cases and high-grade squamous 
intraepithelial lesion (H-SIL) was detected in 1 
(10%) case. Between them, the 60% (6/10) 
showed a histological lesion (4 CIN1 and 2 
CIN2+) (Table 2).
HPV genotyping test was performed on 33 
women with baseline hr-HPV+/PapTest- which, 
9 (27.3%) resulted hr-HPV+/PapTest+ (one 
woman was excluded due to insufficient HC2 
residual material to perform the molecular 
analysis), 13 (39.4%) resulted hr-HPV+/PapTest- 
and 11 (33%) resulted hr-HPV- at the 1-year 
recall.
Most frequent genotype detected was HPV 16, 
identified in 16/33 (48.5%) baseline and 8/22 
(36.4%) 1-year recall hr-HPV positive women 
(Figure 2); between the 8 women positive to 
HPV16 at the 1-year recall, the 50% (4/8) 
showed a histological lesion (3 CIN1 and 1 
CIN2+). The HPV18 was observed in 8/33 (24%) 
and 4/22 (18%) women baseline and 1-year 
recall hr-HPV+ respectively; in any case we 
didn’t observe a histological lesion. Moreover, 
we identified at base line 6/33 (18%) co-infec-
tion of HPV 16 with other HPV type (HPV 18, 31, 
70); the 66.7% (4/6) of these co-infection was 
due to HPV16 with HPV18 (Table 2). At the 
1-year recall only 1 co-infection (HPV16/70) 
was persistent without shows histological 
Table 2. Results of the genotyping test at the 
baseline and at the 1-year recall 
 Baseline 1-year recall
ID Genotype Genotype Cytology Histology
1 33  16  LSIL CIN1
2 58  58  LSIL  
3 16  66*  ASCUS CIN1
4 59  16  LSIL  
5 35  35  LSIL CIN2
6 16  56  LSIL  
7 16 70* 16 70* HSIL CIN1
8 16 18 16  ASCH CIN2
9 33  33  ASCH CIN1
10 31  18  NILM  
11 43**  33  NILM  
12 16  16  NILM  
13 45  18  NILM  
14 16 31 16  NILM  
15 66*  18  NILM  
16 16  16  NILM CIN1
17 18  54**  NILM  
18 18  81**  NILM  
19 81**  81**  NILM  
20 45  45  NILM  
21 16 18 16  NILM  
22 18  18  NILM  
23 16  negative   
24 16  negative   
25 70*  negative   
26 67*  negative   
27 16  negative   
28 16  negative   
29 16  negative   
30 18 16 negative   
31 18  negative   
32 18 16 negative   
33 16  negative   
*Intermediate-risk-HPV/**low-risk-HPV. NILM: Negative 
for Intraepithelial Lesions or Malignancy.
1-year follow-up of Hr-HPV+/PapTest- women
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lesions while, a woman with an HPV16/18 co-
infection at the baseline and only HPV 16 infec-
tion at the 1-year recall developed CIN2+ lesion.
We observed that between women resulted hr-
HPV+/PapTest- at the baseline, the 15% (5/33)
women resulted positive to the hr-HPV test due 
to cross-reaction because they were infected 
with an intermediate- (43, 66, 67) or low-risk 
HPV subtypes (70, 81) (Table 2); therefore, 
none of these developed an histological lesion.
54.5% (12/22) of women hr-HPV+ at the 1-year 
recall presented a persistent infection with the 
same HPV subtypes and 50% was due to 
HPV16. Moreover, 16.7% (2/12) showed a high 
grade histological lesion (CIN2+) and one of 
these was due to HPV16. The 45.5% (10/22) 
hr-HPV+ women at the 1-year recall, developed 
new HPV subtype infection but none of these 
developed a high grade histological lesion.
Discussion
This study describes the follow-up of women 
baseline hr-HPV+/PapTest- who attended the 
new HPV-based screening program organized 
by the Pathology Unit of ICOT Hospital, 
Department of Medical-Surgical Sciences and 
Bio-Technologies of Sapienza University of 
Rome and Screening Unit of Local Health Unit 
of Latina, since 2012. Women hr-HPV+/
PapTest- have been tested from April 2012 to 
June 2013 and they have been followed for 1 
year.
We observed that 30% of invited women 
attended the hr-HPV test and this value is con-
sistent with the regional average (29.3%) 
reported in the previous three years [18] as we 
already described in our previous work [19]. 
The baseline hr-HPV positive rate (5.6%) was in 
line with the value observed in NTCC study 
where the hr-HPV test was performed on 
women aged 35-60 and the proportion of 
women with baseline hr-HPV+/PapTest- was 
comparable to data reported in the literature 
(4% vs. 3.6%) [20]. 
We observed that compliance to 1-year recall of 
women hr-HPV+/PapTest- at baseline was 
74.5% and this value was similar to that 
observed in other Italian national studies [21], 
it was probably due to the success of the infor-
mation campaign carried out in the Italian and 
Latina district. Compared to the population 
screening at baseline, in the group of women 
hr-HPV+/PapTest- at the 1-year-recall we found 
a higher percentage of cases hr-HPV+ (50% vs. 
5.6%); moreover, we detected only a small num-
ber of high-grade lesions (2/298). Indeed, the 
contribution rate for the detection of CIN2+ in 
the group hr-HPV+/PapTest- at the 1-year recall 
was much less than expected (0.67%). Even if 
the data of HPV clearance (50%) was consis-
tent with the literature [15], the 1-year recall 
resulted in an increase of unnecessary colpos-
copies and negatively affected the PPV for 
CIN2+ (1.4%); also, 84.4% (54/64) of women at 
the 1-year recall had no cytological lesions. 
Therefore, to improve the effectiveness of the 
screening program it may be useful to lengthen 
the follow-up period to repeat the hr-HPV test 
(e.g. 18-24 months), in order to increase the 
clearance rate, although a too long follow-up 
Figure 2. Distribution of HPV type detected. 
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period could affect the compliance of colpo- 
scopy.
Nearly 3% (305/9941) of women were referred 
to colposcopy at baseline and at the 1-year 
recall and the colposcopy performed in women 
referred at 1-year recall accounted for 48.8% 
(149/305) of the total. Indeed, the detection 
rate of CIN2+ it was only 0.2‰ at the 1-year 
recall compared to 2.1‰ of the total screened 
cohort; so, an additional triage at this stage 
could decrease the amount of unnecessary 
colposcopies.
The genotyping test allowed us to confirm that 
HPV16 is the most common HPV subtype as 
well as reported in literature and also in our 
previous study [22, 23] both at baseline and at 
the 1-year recall (48.5% and 36.4%) and that 
50% of histological lesions at the recall were 
observed in women infected with this HPV sub-
type. The persistence of infection with an hr-
HPV is most important in the development of 
cervical cancer [24]; in this study we observed 
that 54.5% of women had a persistent infection 
with the same HPV subtype and that 16.7% of 
them developed a CIN2+ histological lesion. 
We noted that this persistence was linked prev-
alently to the presence of HPV16 (50%) effec-
tively, infection with HPV16 tend to persist lon-
ger than with other HPV subtypes regulating the 
proliferation and promoting the neoplastic 
transformation of epithelial cells [25]. 
HPV18 represents the second HPV subtype 
responsible of the development of cervical can-
cer [22]; we observed that it was present in 
24% and 18% of women hr-HPV+ at baseline 
and 1-year recall respectively but in our study 
we observed that HPV18 did not cause cervical 
lesions probably due to the age of the exam-
ined women (35-64). This data is in agreement 
with the hypothesis already considered by us 
that the proportion of high grade lesions 
caused by HPV18 is prevalent among young 
women [19, 26].
It is known that co-infection with HPV subtypes 
could lead to cervical lesions [27] and its role is 
studied for the possible implication in vaccine 
efficiency [28]. In our study 18% of women hr-
HPV+ at baseline presented a co-infection and 
66.7% was due to HPV16 with HPV18. We 
observed that a woman with an HPV 16 persis-
tent infection and with an HPV16-18 co-infec-
tion at baseline showed a high grade cervical 
lesion at the recall.
The use of cytological triage in combination 
with the hr-HPV test was recommended by the 
Italian national guidelines to improve the detec-
tion rate of high grade CIN and to reduce col-
poscopy referral rate, especially in women aged 
35-64 [3]. Indeed, the hr-HPV test alone deter-
mined a high rate of positive tests and this is 
sometimes due to a cross-reaction with inter-
mediate or low risk HPV subtype that does not 
determine a cervical lesion [29]. In this study, 
we observed that at baseline in 5/33 women 
(15%) the positivity to the hr-HPV test was the 
consequence of a cross-reactivity with non-
oncogenic HPV types and this data was compa-
rable to the literature [29]; indeed, they did not 
show a cytological alteration at the 1-year recall 
but, even if only little, the cross-reactions 
increased the number of colposcopies. Our 
data, even if it needs to be confirmed on a larg-
er population, could lead us to speculate that it 
may be more appropriate to lengthen the fol-
low-up period of baseline hr-HPV+/PapTest- 
women in order to reduce unnecessary colpos-
copies without increasing the risk of CIN2+.
Moreover, as already described in our previous 
study the genotyping of HPV16-18 at baseline 
may be a useful tool but not as alternative 
method to cytological triage [22]. However, it 
could be also useful to identify HPV16 persis-
tent infections and HPV16 and 18 co-infections 
in order to discover the CIN2+ lesions in hr-
HPV+/PapTest- women independently of the 
follow-up period.
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